Home › Funds › JOHNSON & JOHNSON › CTNM

JOHNSON & JOHNSON position in CTNM

CONTINEUM THERAPEUTICS INC · Health Care

JOHNSON & JOHNSON reported holding 1,979,173 shares of CTNM (CONTINEUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$26.6M, representing 3.49% of its reported portfolio and ranking #5 among its reported holdings. JOHNSON & JOHNSON has disclosed CTNM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)1.98M sh
Reported value held$26.56M
Portfolio Weight3.49%
First reportedQ2 2024
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How JOHNSON & JOHNSON's CTNM position evolved

JOHNSON & JOHNSON first disclosed a stake in CTNM in Q2 2024 at 1,979,173 shares (US$34.9M). The position peaked in Q3 2024 at 1,979,173 shares, worth US$37.9M. Across 10 filings, JOHNSON & JOHNSON held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,979,173 shares valued at US$26.6M.

Quarter by quarter

QuarterSharesValueChange
Q2 2024 1.98M $34.85M New
Q3 2024 1.98M $37.88M Hold
Q4 2024 1.98M $28.99M Hold
Q1 2025 1.98M $13.81M Hold
Q2 2025 1.98M $8.13M Hold
Q3 2025 1.98M $23.26M Hold
Q4 2025 1.98M $22.62M Hold
Q1 2026 1.98M $25.85M Hold
Q2 2026 1.98M $32.44M Hold
Q3 2026 1.98M $26.56M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CTNM and 13F data

CTNM (CONTINEUM THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in CTNM — the largest reported positions include MONTANOVA CAPITAL, LLC (US$46.6M), GREAT POINT PARTNERS LLC (US$15.1M), Ikarian Capital, LLC (US$13.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CTNM

All CTNM fund holders →

FAQ

How long has JOHNSON & JOHNSON held CTNM?

JOHNSON & JOHNSON has disclosed CTNM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is JOHNSON & JOHNSON's current position in CTNM?

As of Q3 2026, JOHNSON & JOHNSON holds 1.98M shares of CTNM (CONTINEUM THERAPEUTICS INC), valued at $26.56M, representing 3.49% of its reported portfolio and ranking #5.

Has JOHNSON & JOHNSON been buying or selling CTNM?

In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in CTNM. The position peaked in Q3 2024 at 1.98M shares.

Which other funds hold CTNM?

Other major institutional holders of CTNM include MONTANOVA CAPITAL, LLC, GREAT POINT PARTNERS LLC, Ikarian Capital, LLC, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.